General Information:

Id: 1,985 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Rattus norvegicus
male
article
Reference: Carlsson PO et al.(1998) Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats Diabetologia 41: 127-133 [PMID: 9498644]

Interaction Information:

Comment Infusion of ATII induced a dose-dependent and pronounced hypertension in all animals.
Formal Description
Interaction-ID: 15574

gene/protein

Angiotensin II

increases_activity of

phenotype

hypertension

Comment Administration of the two highest doses of ATII led to a slight hyperglycaemia.
Formal Description
Interaction-ID: 15575

gene/protein

Angiotensin II

increases_activity of

phenotype

hyperglycemia

if given in high doses
Comment ATII caused a dose-dependent decrease in both whole pancreatic and islet blood flow.
Formal Description
Interaction-ID: 15576

gene/protein

Angiotensin II

increases_activity of

phenotype

decreased blood flow velocity

in pancreas, in pancreatic islets
Comment Saralasin is a competitive inhibitor of angiotensin II.
Formal Description
Interaction-ID: 15582

drug/chemical compound

Saralasin

decreases_activity of

gene/protein

Angiotensin II

Comment Enalaprilate affected neither basal nor glucose-stimulated insulin release, whereas angiotensin II delayed the first phase of insulin release in response to glucose. The effect of angiotensin II was probably due to initial marked vasoconstriction. The retardation of insulin release could be avoided by adding angiotensin II to the perfusion medium 20 min before glucose administration, i. e. so that the vasoconstriction had disappeared when glucose-stimulation began.
Formal Description
Interaction-ID: 15587

gene/protein

Angiotensin II

affects_activity of

in pancreas